SCHEMBL994359

SCHEMBL994359

[CH2]C(COCCCCCCCC/C=C\CCCCCCCC)OCCCCCCCC/C=C\CCCCCCCC

nearest known ligand 0.57

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 2/20 0.50
LPAR3 Q9UBY5 2/20 0.50
ALDH1A1 P00352 1/20 0.47
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
FAAH O00519 2/20 0.44
TRPV1 Q8NER1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20573193 1.00 LPAR1 (0.50) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL15319711 0.95 ALDH1A1 (0.55) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL21248514 0.95 ALDH1A1 (0.55) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL4300775 0.93 ALDH1A1 (0.52) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL11042865 0.89 USP2 (0.50) LPAR1LPAR3
SCHEMBL2839409 0.89 USP2 (0.50) LPAR1LPAR3
SCHEMBL17629258 0.89 USP2 (0.50) LPAR1LPAR3
SCHEMBL11572401 0.89 USP2 (0.50) LPAR1LPAR3
SCHEMBL2835919 0.89 USP2 (0.50) LPAR1LPAR3
SCHEMBL2420872 0.89 USP2 (0.50) LPAR1LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110268048-B Generation of atrial and ventricular cardiomyocyte lineages from human pluripotent stem cells 大学健康网络 2024-07-09 CN disclosed
CN-117794951-A Claudin 18.2T cell antigen conjugate and application thereof 特拉姆维拉免疫美国有限公司 2024-03-29 CN disclosed
CN-111479925-B T cell-antigen conjugates with Y182T mutations and methods and uses thereof 麦克马斯特大学 2024-03-08 CN disclosed
CN-117480249-A Stem cells comprising unrearranged T Cell Receptor (TCR) loci and methods of use thereof 桑尼布鲁克研究所 2024-01-30 CN disclosed
CN-117396513-A Combination therapy for the treatment of cancer 葛兰素史密斯克莱知识产权发展有限公司 2024-01-12 CN disclosed
CN-116744948-A Cells comprising T cell antigen conjugates and uses thereof 麦克马斯特大学 2023-09-12 CN disclosed
CN-116333108-A Antibodies to amyloid beta 英属哥伦比亚大学 2023-06-27 CN disclosed
CN-114651068-A Chimeric co-stimulatory receptors and methods and uses thereof 麦克马斯特大学 2022-06-21 CN disclosed
CN-1954073-B Modified Bouganin proteins, cytotoxins and methods and uses thereof MERCK PATENT GMBH 2013-01-16 CN disclosed
EP-2453918-A2 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME Novartis AG (CH) 2012-05-23 EP disclosed
WO-2011008974-A2 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME NOVARTIS AG (CH) 2011-01-20 WO disclosed
CN-1954073-A Modified Bouganin proteins, cytotoxins and methods and uses thereof MERCK PATENT GMBH (DE) 2007-04-25 CN disclosed
EP-1261379-A2 GENETIC MODIFICATION OF THE LUNG AS A PORTAL FOR GENE DELIVERY GENZYME CORPORATION (US) 2002-12-04 EP disclosed
WO-2002055110-A2 METHODS FOR TREATING BLOOD COAGULATION DISORDERS GENZYME CORP (US) 2002-07-18 WO disclosed
WO-2002009770-A1 USE OF RAPAMYCIN TO INHIBIT IMMUNE RESPONSE AND INDUCE TOLERANCE TO GENE THERAPY VECTOR AND ENCODED TRANSGENE PRODUCTS GENZYME CORPORATION (US) 2002-02-07 WO disclosed
WO-2001060414-A2 GENETIC MODIFICATION OF THE LUNG AS A PORTAL FOR GENE DELIVERY GENZYME CORPORATION (US) 2001-08-23 WO disclosed